Home

April 5, 2021

Regulatory considerations for cellular and gene therapy products in EU and US: A comparative analysis

March 8, 2021

End-to-end pharmacovigilance support for a UK-based pharmaceutical company

APCER’s Pharmacovigilance (PV) team supported a client’s expansion into new markets by setting up a
March 8, 2021

Setting up Agile PV operations for a US based Pharma company

APCER’s Pharmacovigilance (PV) team helped a biotech pharmaceutical company with set up, training and database
March 8, 2021

Enabling global expansion by establishing an integrated PV system

APCER helped a global pharmaceutical company in establishing a collaborative global pharmacovigilance (PV) governance model;
February 18, 2021

Classification of cellular therapy and gene therapy (CGT) products: How regulators are working with industry

January 12, 2021

Importance of Engaging a Safety Partner Early in the Drug Life Cycle

Ms. Jeanne Schow, Vice President & US Head of Business Development talks the key benefits
January 10, 2021

Virtual Auditing

Our team of experienced auditors help the bio-pharma companies achieve process excellence and regulatory compliance.
January 6, 2021

APCER Factsheet

Snapshot of end-to-end Safety services offered by APCER Life Sciences. We provide comprehensive drug safety/pharmacovigilance,
December 24, 2020

Need for successful launch of Mass Vaccination: Is the world ready?

December 11, 2020

Advanced Therapy Medicinal Products – The Next Therapeutic Revolution

Dr. Vineet Kacker, Managing Director & Global Technical Head talks about the how Advanced Therapy
November 5, 2020

Human medicinal products containing nitrosamine impurities: Regulatory landscape in the United States and the European Union